Multicentre European study of thalamic stimulation in parkinsonian and essential tremor

P Limousin, J D Speelman, F Gielen, M Janssens, and study collaborators

Abstract

Objectives—Thalamic stimulation has been proposed to treat disabling tremor. The aims of this multicentre study were to evaluate the efficacy and the morbidity of thalamic stimulation in a large number of patients with parkinsonian or essential tremor.

Methods—One hundred and eleven patients were included in the study and 110 were implanted either unilaterally or bilaterally. Patients were evaluated with clinical scales, before and up to 12 months after surgery.

Results—Upper and lower limb tremor scores were reduced in both groups. Eighty-five per cent of the electrodes satisfied the arbitrary criteria of two point reduction in rest tremor reduction in the parkinsonian tremor group and 89% for postural tremor reduction in the essential tremor group. In the parkinsonian tremor group, limb akinesia and limb rigidity scores were moderately but significantly reduced. Axial scores were unchanged. In the essential tremor group, head tremor was significantly reduced only at 3 months and voice tremor was non-significantly reduced. Activities of daily living were improved in both groups. Changes in medication were moderate. Adverse effects related to the surgery were mild and reversible.

Conclusions—Thalamic stimulation was shown to be an effective and relatively safe treatment for disabling tremor. This procedure initially applied in a very limited number of centres has been successfully used in 13 participating centres.

Keywords: thalamic stimulation; Parkinson’s disease; essential tremor

Thalamotomy for the treatment of tremor was introduced more than 40 years ago. The introduction of levodopa in the treatment of Parkinson’s disease in 1967, and the morbidity related to thalamotomy, particularly bilateral procedures, made thalamotomy in Parkinson’s disease an “outmoded therapy”. In 1987, Benabid et al successfully treated parkinsonian patients with drug resistant tremor with chronic stimulation of the ventrointermediate nucleus of the thalamus. This followed the pioneer works of several neurosurgeons who applied electrical stimulation to different thalamic nuclei to treat tremor or other dyskinesias. In 1991, Benabid et al reported on 26 patients with Parkinson’s disease and six patients with essential tremor and found a permanent complete or major suppression of tremor in 88% of the patients. Eleven patients were implanted and stimulated on both sides. The surgical morbidity was low making bilateral surgery possible. Other teams confirmed these findings. These preliminary studies concerned a small number of patients, or included only unilaterally stimulated patients, assessed mainly the effects on tremor, and used a global scale for the evaluation of the outcome.

In 1992 we started a multicentre European study to evaluate the efficacy and the morbidity of chronic unilateral or bilateral thalamic stimulation in a larger population of patients with severe disabling parkinsonian or essential tremor. Moreover, the effects of thalamic stimulation were evaluated for other parkinsonian symptoms and activities of daily living. The effects of unilateral stimulation were assessed on contralateral and ipsilateral symptoms. We report up to 12 month follow up of 110 patients operated on in 13 European neurosurgical centers.

Patients and methods

PATIENTS

One hundred and eleven patients (table 1), 74 with parkinsonism and 37 with essential tremor, were included between August 1992 and November 1994, according to the following criteria: (1) idiopathic Parkinson’s disease or essential tremor with pharmacotherapy resistant tremor, present during the major part of the day; (2) tremor score rated 3 or 4 on the five point tremor scales (0=no tremor to 4=very severe tremor, see assessments) for the limb intended for treatment; (3) ability to abide by the protocol and to operate the stimulator. Drugs, levodopa preparations, and dopamine agonists for parkinsonian patients, and propranolol and primidone for essential tremor patients, had to have been prescribed at maximal tolerated dosages for at least 3 months before enrollment. Two parkinsonian patients fulfilled the clinical criteria for Parkinson’s disease with the exception of levodopa responsiveness. Patients were excluded from the study if they had (1) previous thalamotomy on the side of implantation; (2) significant brain atrophy or structural brain damage on CT or MRI; (3) other disorders that may interfere with the efficacy of the treatment of tremor, such as marked cognitive dysfunction, active psychiatric symptoms, and concurrent neurological or other uncontrolled medical disorders. One parkinsonian patient was withdrawn from the study before implantation because he developed...
difficulty breathing early in the procedure. The study was approved by the hospital ethics committees and the patients gave written informed consent.

**ASSESSMENT**

Parkinsonian patients were assessed using the unified Parkinson’s disease rating scale (UPDRS) version 3.0.18 All parkinsonian patients were scored in practically defined condition (12 hours without medication). Patients with essential tremor were assessed according to the essential tremor rating scale (ETRS).19 Both scales are compound rating scales with an impairment, disability, and activities of daily living (ADL) section. Patients were scored less than 1 month preoperatively for baseline assessment and 1 week, and 3, 6, and 12 months postoperatively. Follow up scores were performed with the stimulator switched off and on. In every centre, assessments were performed by a neurologist specialised in movement disorders.

**SURGICAL TECHNIQUE**

The implantation and testing of the electrodes was performed under local anaesthesia. The target structure was the ventrointermediate thalamic nucleus (Vim). For the calculations of the coordinates of Vim, nine centres used positive contrast ventriculography, three in association with MRI. Three other centres used CT only and one centre MRI only. For the introduction of a test electrode a burr hole was made 2–3 cm lateral from the midline and just in front of the coronal suture. In addition to the imaging, two surgical centres used semimicro or microrecording to help in the location of Vim. In all centres test stimulations with high frequency (≥100 Hz) were performed allowing the study of tremor amplitude, diffusion of stimulation to the internal capsule, threshold for paraesthesias, and speech disturbances. Additionally some centres also applied low frequency stimulation (2 Hz–4 Hz) to study diffusion of the stimulation to the internal capsule. If the results were not satisfactory the test electrode was moved in a direction determined by the obtained stimulation effect. If high frequency stimulation suppressed the tremor without or with only slight transient adverse effect, the permanent quadipolar stimulation electrode (Model 3387, Medtronic, Minneapolis, USA) was implanted. Initially, all centres connected the electrode with external extension wires through the skin enabling postoperative test stimulation. A few days later if the patient obtained satisfactory results, the stimulator (Itrel®–II, Medtronic, Minneapolis, USA) was implanted subcutaneously below the collar bone, usually under general anaesthesia, and connected with a subcutaneous extension to the electrode. During the study four centres decided to connect the stimulator immediately after implantation without the postoperative testing period, if test stimulations during the implant surgery showed good tremor suppression.

**POSTOPERATIVE CARE**

After implantation and at each follow up, the stimulation parameters—frequency, pulse width, and voltage—were adjusted for optimal tremor control with minimum side effects. Bipolar or monopolar stimulation could be programmed using one or a combination of the four contacts. Patients could switch the stimulator on and off using a magnet and were advised to switch the stimulator off at night. They could also use the magnet to switch the stimulation back on if it happened to be accidentally stopped by a strong environmental magnetic field. For the first 3 months after implantation the medications were kept unchanged, except in cases of unacceptable drug induced side effects.

**DATA ANALYSIS**

Data are presented as mean (SD) and number of values (n) at baseline, and 3 and 12 months follow up. Because of missing data we compared some results on a smaller number of patients. This number is given in the various tables. The effect of the stimulation (on stimulation versus off stimulation), the effect of the procedure (before surgery versus on stimulation), and the effect of implantation (before surgery versus off stimulation) on clinical score were studied. Activities of daily living, dyskinesias, and drug dosage at 3 and 12 months follow up were compared with baseline. The UPDRS items 32 and 33 evaluating the intensity and the duration of dyskinesias were combined and compared between baseline and 12 months in the group of patients who had a non-zero score at baseline. The same analysis was done for the UPDRS item 34 evaluating off dystonia. We calculated the number of electrodes allowing a reduction of at least two points of the upper limb, rest tremor score in the parkinsonian tremor group, and postural tremor score in the essential tremor group (maximum score four points). The different comparisons are detailed in the results section. We used the non-parametric Wilcoxon matched pairs signed rank sum test because of the number of data points per test and the expected skewed distribution of the test statistics. All p values are given for two sided tests. To reduce the overall risk of type I error the individual level of significance was set at p=0.005.

**Results**

We present in the first part the effects of thalamic stimulation on symptomatology of parkinsonian patients, in the second part the effect on patients with essential tremor, and in

---

**Table 1 Patient characteristics**

<table>
<thead>
<tr>
<th></th>
<th>Parkinson’s disease</th>
<th>Essential tremor</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of patients</td>
<td>73</td>
<td>37</td>
</tr>
<tr>
<td>Unilateral/bilateral implant (n)</td>
<td>57 / 16</td>
<td>28 / 9</td>
</tr>
<tr>
<td>Sex</td>
<td>26 F / 47 M</td>
<td>13 F / 24 M</td>
</tr>
<tr>
<td>Mean age at implant (y)</td>
<td>61.5 (10.8)</td>
<td>63.1 (12.7)</td>
</tr>
<tr>
<td>Mean duration of disease (y)</td>
<td>10.0 (5.6)</td>
<td>26.6 (14.5)</td>
</tr>
</tbody>
</table>

Values in parentheses are SD; the patient not implanted is not included in the table.
Table 2  Effect of unilateral thalamic stimulation (total number of patients 57) on treated and non-treated hemibody symptoms, parkinsonian tremor group

<table>
<thead>
<tr>
<th>Score (item of the UPDRS)</th>
<th>Hemibody</th>
<th>3 months</th>
<th>12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tremor (items 20 limbs + 21)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treated</td>
<td>8.04 (2.54) [52]</td>
<td>7.46 (3.07) [50]</td>
<td>1.73 (1.88) [52] *†</td>
</tr>
<tr>
<td>Non-treated</td>
<td>3.00 (2.92) [52]</td>
<td>3.31 (3.26) [49]</td>
<td>2.55 (2.86) [52]</td>
</tr>
<tr>
<td>Rigidty (item 22 limbs)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treated</td>
<td>1.87 (1.84) [52]</td>
<td>1.76 (1.46) [51]</td>
<td>1.19 (1.31) [52] *†</td>
</tr>
<tr>
<td>Non-treated</td>
<td>1.19 (1.53) [52]</td>
<td>1.22 (1.29) [51]</td>
<td>1.10 (1.32) [52]</td>
</tr>
<tr>
<td>Akinesia (items 23-26)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treated</td>
<td>6.83 (3.37) [52]</td>
<td>7.45 (3.67) [51]</td>
<td>4.38 (2.72) [52] *†</td>
</tr>
<tr>
<td>Non-treated</td>
<td>3.52 (3.27) [52]</td>
<td>4.45 (3.56) [51]</td>
<td>4.00 (1.28) [52]</td>
</tr>
</tbody>
</table>

Values are mean (SD) [No of patients].

*p<0.001 v baseline; †p<0.001 v off stimulation.

**Figure 1** UPDRS subscores evaluation: upper limb rest tremor: UPDRS 20(A), upper limb postural/action tremor:UPDRS 21 (B), and lower limb rest tremor UPDRS 20 (C) for the hemibody contralateral to surgery, in the parkinsonian tremor group.

**PARKINSONIAN GROUP (n=73)**

**Effect of thalamic stimulation on tremor**

The effects of stimulation on tremor (on stimulation versus off stimulation), procedure (before surgery versus on stimulation), and implantation (before surgery versus off stimulation) on tremor scores were first analysed for the total population of 73 patients (fig 1). At 3 and 12 months follow up, both upper and lower limb tremor were significantly reduced by stimulation and by the procedure (p<0.001). No significant effect by the implantation alone was shown. Rest tremor of the contralateral upper limb was reduced at least two points in 85% of the electrodes.

This analysis was repeated separately for the subgroup of unilaterally implanted patients to assess ipsilateral effects (table 2). The significant reduction of contralateral tremor by the stimulation and the procedure was confirmed in this subgroup at 3 and 12 months. Before surgery, patients had generally very mild tremor on the hemibody ipsilateral to surgery. At 3 months, off stimulation ipsilateral tremor was non-significantly increased in comparison with baseline and was significantly reduced by the stimulation. At 12 months, off stimulation ipsilateral tremor was back to baseline and the effect of the stimulation was not significant.

**Effect of thalamic stimulation on other symptoms**

The procedure and stimulation significantly reduced the motor score of the UPDRS for the total population of 73 patients (table 3). The reduction of the score was mainly related to the effect of stimulation as off stimulation score remained the same (table 3). Symptoms other than tremor were very mild before surgery. Stimulation significantly reduced contralateral akinesia and rigidity (details of the scores in table 3) at 3 and 12 months follow up. Stimulation had the same effect on contralateral akinesia and rigidity in the group of unilaterally treated patients, whereas ipsilateral akinesia and rigidity remained unchanged (table 2).

Axial symptoms, speech, postural stability, and gait were not affected by unilateral or bilateral stimulation (table 4). Levodopa induced dyskinesias, evaluated by the combination of UPDRS items 32 and 33, were slightly but non-significantly reduced from 2.00 (SD 1.56) before surgery to 1.45 (SD 0.89) 12 months after surgery. Off dystonia, evaluated by the UPDRS item 34 was unchanged, 0.76 (SD 0.44) before surgery and 0.71 (SD 0.47) after surgery.

**Functional improvement**

Schwab and England and UPDRS II scores were improved after surgery, as a consequence of changes in motor function (table 3). Especially, item 8 (handwriting) and item 16 (invalidity related to tremor) of the UPDRS II, which are specifically influenced by tremor, were significantly reduced.

**Drug modifications**

Seven patients had no antiparkinsonian drug at the time of the surgery. Five of them had tried levodopa at the maximum tolerated dose and stopped because tremor was not effectively controlled. For the two other patients the neurologist in charge had decided not to try levodopa, although it is advised to try levodopa at maximum tolerated dosage before surgery.

The effects of stimulation (on stimulation versus off stimulation), procedure (before surgery versus on stimulation), and implantation (before surgery versus off stimulation) on tremor scores were first analysed for the total population of 73 patients (fig 1). At 3 and 12 months follow up, both upper and lower limb tremor were significantly reduced by stimulation and by the procedure (p<0.001). No significant effect by the implantation alone was shown. Rest tremor of the contralateral upper limb was reduced at least two points in 85% of the electrodes.
Values are mean (SD) [No of patients].

*p<0.001 vs baseline, †p<0.001 vs off stimulation.

Table 5 Medications relevant to study before and 12 months after surgery

<table>
<thead>
<tr>
<th>Parkinson’s disease</th>
<th>Baseline</th>
<th>12 months follow up</th>
<th>Essential tremor</th>
<th>Baseline</th>
<th>12 months follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levodopa</td>
<td>649 (522) [65]</td>
<td>610 (436) [65]</td>
<td>610 (436) [65]</td>
<td>649 (522) [65]</td>
<td>610 (436) [65]</td>
</tr>
<tr>
<td>Dopamine agonists</td>
<td>[33]</td>
<td>[28]</td>
<td>[1]</td>
<td>[0]</td>
<td></td>
</tr>
<tr>
<td>Anticholinergic drugs</td>
<td>[13]</td>
<td>[12]</td>
<td>[0]</td>
<td>[0]</td>
<td></td>
</tr>
<tr>
<td>MAO-B inhibitors</td>
<td>[15]</td>
<td>[11]</td>
<td>[0]</td>
<td>[0]</td>
<td></td>
</tr>
<tr>
<td>Primidone</td>
<td>[3]</td>
<td>[0]</td>
<td>413 (330) [9]</td>
<td>153 (264) [9]</td>
<td></td>
</tr>
</tbody>
</table>

Mean dose (mg/day) [SD] [number of patients].

Table 6 Effect of thalamic stimulation on essential tremor and activity of daily living

<table>
<thead>
<tr>
<th>Score (from ETRS)</th>
<th>Group</th>
<th>Baseline</th>
<th>3 months</th>
<th>12 months</th>
<th>Off stimulation</th>
<th>On stimulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tremor ETRS (item 1-9)</td>
<td>All</td>
<td>19.21 (8.22) [34]</td>
<td>15.24 (6.82) [33]</td>
<td>7.88 (5.17) [33]†</td>
<td>17.21 (7.33) [33]</td>
<td>8.65 (5.86) [34]†</td>
</tr>
<tr>
<td>Voice tremor (item 3)</td>
<td>All</td>
<td>0.63 (0.69) [35]</td>
<td>0.41 (0.70) [34]</td>
<td>0.31 (0.53) [35]</td>
<td>0.54 (0.70) [35]</td>
<td>0.40 (0.06) [35]</td>
</tr>
<tr>
<td>Head tremor (item 4)</td>
<td>All</td>
<td>1.11 (0.60) [9]</td>
<td>0.22 (0.44) [9]</td>
<td>0.33 (0.50) [9]</td>
<td>0.42 (0.76) [26]</td>
<td>0.31 (0.74) [26]</td>
</tr>
<tr>
<td></td>
<td>Unilateral</td>
<td>1.00 (1.47) [26]</td>
<td>1.08 (1.26) [26]</td>
<td>0.64 (0.95) [25]</td>
<td>0.89 (0.33) [9]</td>
<td>0.67 (0.50) [9]</td>
</tr>
<tr>
<td></td>
<td>Bilateral</td>
<td>2.22 (1.30) [9]</td>
<td>1.33 (1.12) [9]</td>
<td>0.44 (0.73) [9]†</td>
<td>1.09 (1.62) [35]</td>
<td>0.71 (1.30) [35]</td>
</tr>
<tr>
<td>ADL ETRS (item 15-21)</td>
<td>All</td>
<td>14.88 (4.28) [32]</td>
<td>15.27 (6.59) [26]</td>
<td>3.90 (4.64) [30]†</td>
<td>14.92 (7.20) [24]</td>
<td>2.93 (6.49) [20]†</td>
</tr>
<tr>
<td></td>
<td>Unilateral</td>
<td>25.43 (7.39) [15]</td>
<td>22.68 (8.43) [15]</td>
<td>13.50 (7.60) [34]†</td>
<td>25.21 (7.20) [34]</td>
<td>14.26 (6.49) [34]†</td>
</tr>
</tbody>
</table>

Values are mean (SD) [number of patients].

*p<0.001 vs baseline, †p<0.001 vs off stimulation, ‡p<0.005 vs unilateral.

Sixty five patients were still taking levodopa at surgery. The number of patients using medications was not changed and the mean doses were non-significantly reduced 12 months after surgery (table 5).

ESSENTIAL TREMOR (n=37)

Effect of thalamic stimulation on essential tremor

The effect of stimulation (on stimulation versus off stimulation), procedure (before surgery versus on stimulation), and implantation (before surgery versus off stimulation) on contralateral tremor scores were first analysed for the total group of patients (fig 2). At 3 and 12 months follow up, the stimulation and the procedure significantly reduced postural and action tremor of the upper limb (fig 2, p<0.001). Lower limb tremor was moderate before surgery, and was significantly reduced by the procedure (p<0.001). The effect of the stimulation was significant at 12 months follow up only (p<0.001). A probable persisting microthalamotomy effect decreased tremor even with the stimulator off at 3 months post-surgery. Postural tremor of the contralateral upper limb was reduced by at least two points in 89% of the electrodes. Head and voice tremor were both very mild before surgery (table 6). Head tremor was significantly improved by stimulation at the 3 month follow up only. Bilateral stimulation was more effective on head tremor than unilateral stimulation (table 6). Voice tremor was not significantly reduced after surgery and there was no difference between unilateral and bilateral surgery (table 6). The group of patients with unilateral stimulation was analysed separately to evaluate ipsilateral tremor. Stimulation and the procedure significantly reduced contralateral but not ipsilateral tremor (table 7).

Activities of daily living

The procedure improved items 10–14 of the ETRS which evaluate hand function such as drawing, writing, and pouring and items 15–21 of the ETRS which evaluate activities of daily living (table 6).
Multicentre study on thalamic stimulation

Drugs

Nineteen patients had no antitremor drugs at the time of surgery. The drugs most often used were propranolol and primidone. The number of patients using medications was not changed. The mean doses of propranolol and primidone were reduced 12 months after surgery, but this difference was not significant (table 5).

ADVERSE EFFECTS

One hundred and eleven patients were enrolled in the study; 110 were implanted. One patient developed difficulties breathing in the operating theatre at the time of skin incision; therefore, this patient was not implanted. Four patients had major adverse effects unrelated to surgery or stimulation. Three patients died from causes unrelated to surgery or stimulation, and one patient had a stroke in the contralateral hemisphere 3 months after surgery. He lay on the floor for a prolonged period and developed a skin erosion over the connector. Two patients had subdural haematomas, which resorbed without intervention and left no sequelae. A third patient had a subdural and a thalamic haematoma inducing transient left hemibody neglect which resolved without sequelae. Two patients had an infection of the system. The equipment was temporarily explanted and the patients treated with antibiotics. Two other patients developed subcutaneous haematomas which were evacuated. The electrode was replaced because of unsatisfactory results in five patients. This replacement resulted in a good efficacy in all patients. A transient attentional and cognitive deficit has been described in one patient. Other adverse effects, dysarthria (seven patients: five unilateral stimulation and two bilateral stimulation), disequilibrium (three patients: all bilateral stimulation), dystonia (one patient), were mild, related to the stimulation, and reversible with the change of electrical parameters. Some patients complained additionally of local pain at the implantation site of the pulse generator.

ELECTRICAL PARAMETERS AND CONTACTS

Electrical parameters used for parkinsonian tremor and essential tremor were in the same range (table 8). In both groups voltage was slightly but significantly, increased over 1 year and changes in pulse width and frequency were small. Frequencies over 130 Hz were usually used. Most patients were stimulated at 130 Hz at implant and 185 Hz at 12 months. Monopolar stimulation (one contact negative, the case of the pulse generator positive) was used in most patients. Bipolar stimulation (at least one contact negative and one contact positive) was used when tremor reduction was obtained, with less adverse effects than monopolar stimulation. The stimulated contact was changed over time. Contact 0 (distal) or 1 was used when tremor reduction was obtained, with less adverse effects than monopolar stimulation. The stimulated contact was changed over time. Contact 0 (distal) or 1 was usually placed at the optimal area determined during surgery. These deepest contacts were more often used. At 12 months, stimulation was stopped at night in 48 electrodes (out of 79) in the parkinsonian tremor group and 35 electrodes (out of 44) in the essential tremor group.

### Table 7 Effect of unilateral thalamic stimulation on treated and non-treated hemibody, in the essential tremor group

<table>
<thead>
<tr>
<th>Score (item from ETRS)</th>
<th>Hemibody</th>
<th>3 months</th>
<th>12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Off stimulation</td>
<td>On stimulation</td>
</tr>
<tr>
<td><strong>Upper limb (ETRS 5-6)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treated</td>
<td>7.27 (1.91) [26]</td>
<td>6.04 (2.31) [26]</td>
<td>1.42 (1.33) [26]</td>
</tr>
<tr>
<td>Non-treated</td>
<td>5.69 (2.81) [26]</td>
<td>5.96 (3.10) [26]</td>
<td>5.50 (3.11) [26]</td>
</tr>
<tr>
<td><strong>Lower limb (ETRS 8-9)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treated</td>
<td>1.81 (2.64) [26]</td>
<td>1.15 (2.03) [26]</td>
<td>0.50 (1.03) [26]</td>
</tr>
<tr>
<td>Non-treated</td>
<td>1.08 (2.13) [26]</td>
<td>0.85 (1.19) [26]</td>
<td>0.73 (1.22) [26]</td>
</tr>
</tbody>
</table>

Values are mean (SD) [No of patients].

*p<0.001, †p<0.005 v baseline; ‡p<0.001; §p<0.005 v off stimulation.

Figure 2  ETRS subscores evaluation: upper limb rest tremor: (ETRS 5 or 6) (A), upper limb postural tremor: (ETRS 5 or 6) (B), upper limb action/intention tremor: (ETRS 5 or 6) (C), and lower limb rest/postural/action tremor (ETRS 8 or 9) (D) for the hemibody contralateral to surgery, in the essential tremor group. *p<0.005 v baseline; †p<0.005 v stimulation.
Table 8  Electrical parameters of stimulation at implant, 3 month, and 12 month follow up

<table>
<thead>
<tr>
<th></th>
<th>Parkinson’s disease</th>
<th>Essential tremor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Implant 3 months</td>
<td>12 months</td>
</tr>
<tr>
<td></td>
<td>Implant 3 months</td>
<td>12 months</td>
</tr>
<tr>
<td>Voltage (V)</td>
<td>1.97 (0.87) [85]</td>
<td>1.93 (0.79) [45]</td>
</tr>
<tr>
<td>(SD)</td>
<td></td>
<td>2.17 (0.81) [44]*</td>
</tr>
<tr>
<td>Pulse width (s)</td>
<td>89.65 (45.44) [66]</td>
<td>92.00 (44.04) [45]</td>
</tr>
<tr>
<td>Rate (Hz)</td>
<td>147.50 (24.38) [86]</td>
<td>151.56 (23.74) [45]</td>
</tr>
<tr>
<td>Monopolar</td>
<td>66 [69]</td>
<td>[38]</td>
</tr>
<tr>
<td>Bipolar</td>
<td>23 [15]</td>
<td>[8]</td>
</tr>
<tr>
<td>Contacts‡</td>
<td>0 / - / + / off</td>
<td>21 / 1 / 24</td>
</tr>
<tr>
<td></td>
<td>1 / - / + / off</td>
<td>21 / 7 / 18</td>
</tr>
<tr>
<td></td>
<td>2 / - / + / off</td>
<td>11 / 1 / 29</td>
</tr>
<tr>
<td></td>
<td>3 / - / + / off</td>
<td>1 / 1 / 44</td>
</tr>
<tr>
<td></td>
<td>8 / 3 / 78</td>
<td>2 / 0 / 42</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 / 0 / 42</td>
</tr>
<tr>
<td>Values are mean (SD)</td>
<td>[No of electrodes]. †For each contact (0 to 3), No of patients who have a setting with a negative (-) polarity/a positive (+) polarity/contact off.</td>
<td></td>
</tr>
</tbody>
</table>

Discussion

TREMOR

This study confirms the clear effect of thalamic stimulation on parkinsonian and essential tremor. Upper and lower limb tremor were improved in a large group of patients operated in different centres. Eighty five per cent (parkinsonian tremor) to 89% (essential tremor) of the electrodes gave a reduction of upper limb tremor amplitude satisfying the arbitrary criteria of two point reduction. Unilateral stimulation mainly improved contralateral tremor; therefore, patients with severe bilateral tremor usually needed a bilateral procedure.

In the essential tremor group, head and voice tremor were non-significantly improved after 1 year follow up. These symptoms were very mild before surgery and were not an indication for operation. Therefore the differences are small and might explain why they are not significant. A recent study shows that voice tremor can be improved.28 Head tremor was more improved after a bilateral procedure than after a unilateral one, probably because of the bilateral innervation of neck muscles.

The beneficial effect of the stimulation on limb tremor was maintained over 1 year but the voltage had to be increased. The necessity to increase the voltage could be related to some tolerance effect, or the decrease of the lesion effect of implantation. A previous study in a smaller group of patients has shown that the benefit remains in most patients followed up to 7 years, although a few patients can develop tolerance.19 Tremor reduction improved motor function both for parkinsonian patients and patients with essential tremor. This result is in agreement with a recent study on the effect of thalamic stimulation on disability in a small group of patients.17

OTHER PARKINSONIAN SYMPTOMS

An improvement in limb akinesia and rigidity was seen in the parkinsonian group. Akinesia and rigidity are difficult to assess with severe tremor which could have masked their appearance before surgery. However, the decrease in arm akinesia reflects an improvement in hand function whatever the mechanism. A formal assessment of the effects of thalamic stimulation on akinesia and rigidity has not been done before. Thalamotomy improved rigidity but did not improve akinesia in the long term.23

Thalamic stimulation had no effect on axial akinesia, as already shown by a study of gait.23 Therefore, patients disabled only by tremor may be operated on in this target. Other patients should be offered another procedure such as pallidal or subthalamic nucleus surgery which can improve tremor and other symptoms.18–20 Dyskinesias were slightly but non-significantly decreased after surgery in our study. Other groups also did not find a clear antidyskinetic effect.21 Capparos-Lefebvre et al found a significant decrease in dyskinesia related to thalamic stimulation which could be related to a more medial location of the electrode.22 Our protocol did not include a dyskinesia scale; evaluation of dyskinesias was based on questions to the patient (UPDRS items 32 to 34). Therefore, the effect of thalamic stimulation on dyskinesias needs to be studied with a more specific protocol.

ADVERSE EFFECTS

Thalamic implantation had a low rate of severe adverse effects even in bilateral procedures. Most adverse effects were mild and reversible. Thalamotomies are very effective on tremor, but the morbidity, including speech disturbances, disequilibrium, and cognitive dysfunction, limits the number of indications, particularly in cases of bilateral symptoms. Cognitive functions were not evaluated formally during this study but one patient only declared having some transient cognitive impairment after surgery. Previous studies have shown the absence of major cognitive change.30 31 The incidence of haemorrhage was very low in our study; 4% of the patients had an extracerebral haemorrhage without sequel and one patient had a small intracerebral haemorrhage. An 8% risk of haemorrhage was found in a previous thalamic stimulation series of which one quarter were asymptomatic.24 In our study, MRI control was performed only in a few centres. Therefore, we could have missed some asymptomatic bleeds. The risks of persistent adverse effects during thalamotomy and thalamic stimulation are difficult to compare as there is no published comparative study, but one is now in progress in The Netherlands.25 After thalamotomy this risk varies for transient or mild adverse events between 25% and 30% of the operations, and for significant sequelae between 2% and 7% for unilateral surgery and after bilateral thalamotomy adverse events up to 60% were
MULTICENTRE STUDY ON THALAMIC STIMULATION

295

20.

PARAMETERS OF STIMULATION

Voltage was slightly increased over time. Most patients were able to stop the stimulation at night. This is more difficult with parkinsonian tremor than with essential tremor because of the rest component. The quadrupolar electrode was useful as the stimulated contacts were changed over time. The implantation of the electrode induced a transient lesion-like effect on upper limb tremor. This effect had disappeared at the 3 month follow up. Because of this transient effect, electrical parameters often needed adjustment in the first months after surgery.

MEDICATIONS

Antiparkinsonian drugs were unchanged after surgery, probably because some parkinsonian symptoms are not controlled by thalamic stimulation. Also, levodopa has an additive effect to stimulation to control tremor in some patients. Previous studies found that only one third of the patients can decrease drug dosage. Propranolol and primidone dosages were decreased in the essential tremor group but the difference was not significant, probably because of the few patients and the large SD.

In conclusion, in an open, prospective multicentre study the beneficial effects of chronic thalamic stimulation for parkinsonian and essential tremor were confirmed. Moreover, a slight but significant improvement was found for the other parkinsonian symptoms: rigidity and akinesia. In addition, the UPDRS functional score improved significantly. This study was open which might introduce some bias in the assessment; to reduce this risk the assessment was performed independently of the surgical team. Long term comparative studies are needed to determine the respective indication of thalamic, subthalamic nucleus, and pallidal surgery in the treatment of parkinsonian tremor. Bilateral implantation of a stimulation electrode is possible because of the few transient adverse events.

PL and JDS evaluated patients in their group and were responsible for writing the paper. FG and MJ were responsible for data management and analysis. Study group collaborators included a neurosurgeon and a neurologist in Parma (NL), a neurosurgeon and a neurologist in Pisa (MSP), and a neurosurgeon (MRC). All authors were responsible for the manuscript and implanted the patients and they provided comments on the paper. Members of the group are: A Benabid, P Pollak (Grenoble); F Alesch, M Pinter (Vienna); S Rehnström, R Eiberg (Lund); L Augustinsson, B Jörnholm (Gothenburg); B Meyerson, O Söydow (Stockholm); J N’Guyen, C Geny (Paris); D Bosch (Amsterdam); M Hariz, P Johansson (Umea); M Derooyt, P Bourgeois (Roeselare); J Lemaire, F Durit (Clermont Ferrand); T Verina, H B Roberts (Dundee), P D Rumyantsev, Moscow; and J Sutcliffe, J Dick (London). We thank Medtronic, Minneapolis, USA, for financial support and Mr Keith Mullert for his comments on the manuscript.

28. Schuurman PR, Speelman JD, Bosch DA. Thalamic stimulation versus thalamotomy in a prospective randomized trial. In: Abstracts of oral presentations, 12th Meeting of the


Visitors to the world wide web can now access the Journal of Neurology Neurosurgery and Psychiatry either through the BMJ Publishing Group’s home page (http://www.bmjpg.com) or directly by using its individual URL (http://www.jnnp.com). There they will find the following:

- Current contents list for the journal
- Contents lists of previous issues
- Members of the editorial board
- Subscribers’ information
- Instructions for authors
- Details of reprint services.

A hotlink gives access to:

- BMJ Publishing Group home page
- British Medical Association web site
- Online books catalogue
- BMJ Publishing Group books.

The web site is at a preliminary stage and there are plans to develop it into a more sophisticated site. Suggestions from visitors about features they would like to see are welcomed. They can be left via the opening page of the BMJ Publishing Group site or, alternatively, via the journal page, through “about this site”.
Multicentre European study of thalamic stimulation in parkinsonian and essential tremor

P Limousin, J D Speelman, F Gielen, M Janssens and study collaborators

*J Neurol Neurosurg Psychiatry* 1999 66: 289-296
doi: 10.1136/jnnp.66.3.289

Updated information and services can be found at:
http://jnnp.bmj.com/content/66/3/289

These include:

**References**
This article cites 32 articles, 2 of which you can access for free at:
http://jnnp.bmj.com/content/66/3/289#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Movement disorders (other than Parkinsons) (766)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/